You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Zealand Pharma
since
auto-detected in 30 stories
9 months ago
The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss drug.
Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit ○
The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss drug.
11 months ago
Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma ○
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.
Roche shares pop 5% on $5.3 billion obesity drug deal with Zealand Pharma ○
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.
Roche shares pop 5% on $5.3 billion obesity drug deal with Zealand Pharma ○
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.
Roche signs biggest-ever obesity drug deal ○
Swiss pharma group agrees $5.3bn licensing agreement for next-generation treatment made by Zealand Pharma
page 1 of 1